Pfizer Secures FDA Priority Review for HYMPAVZI, Yields 6.3% Dividend
FDA granted Priority Review for Pfizer’s HYMPAVZI supplemental BLA with a Q2 2026 PDUFA action date as full-year 2025 revenues totaled $62.6 billion, down 2% operationally. Pfizer yields 6.3% and could gain from PF-3944’s June GLP-1 trial results, though patent cliffs looming in 2027-2028 add risk.
1. Regulatory Update on HYMPAVZI
The FDA accepted Pfizer’s supplemental Biologics License Application for HYMPAVZI and granted Priority Review, assigning a PDUFA action date in Q2 2026 for the expanded hemophilia A and B indication in patients aged six and older.
2. 2025 Financial Performance
Pfizer reported full-year 2025 revenues of $62.6 billion, reflecting a 2% operational decline, with Q4 revenues of $17.6 billion down 3% operationally compared with the prior year.
3. Dividend Yield and GLP-1 Pipeline
Pfizer currently offers a 6.3% dividend yield as investors anticipate potential gains from PF-3944’s GLP-1 weight-loss trial data expected in June, while looming patent cliffs in 2027-2028 present a notable risk to future growth.